| Title |
Dose Response of Gabapentin Enacarbil versus Placebo in Subjects with Moderate-to-Severe Primary Restless Legs Syndrome
|
|---|---|
| Published in |
CNS Drugs, December 2012
|
| DOI | 10.2165/11634870-000000000-00000 |
| Pubmed ID | |
| Authors |
Susan A. Van Meter, Sarah T. Kavanagh, Samantha Warren, Ronald W. Barrett |
| Abstract |
The efficacy and tolerability of gabapentin enacarbil (Horizant®; GlaxoSmithKline, Brentford, UK) has been demonstrated in several restless legs syndrome (RLS) phase II and phase III clinical studies at various doses from 600 mg to 2400 mg. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Egypt | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Italy | 1 | 4% |
| Unknown | 26 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 5 | 19% |
| Other | 4 | 15% |
| Researcher | 3 | 11% |
| Student > Bachelor | 2 | 7% |
| Student > Ph. D. Student | 1 | 4% |
| Other | 3 | 11% |
| Unknown | 9 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 30% |
| Neuroscience | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Psychology | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 12 | 44% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 January 2013.
All research outputs
#22,756,649
of 25,371,288 outputs
Outputs from CNS Drugs
#1,312
of 1,387 outputs
Outputs of similar age
#256,158
of 286,276 outputs
Outputs of similar age from CNS Drugs
#63
of 66 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,387 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 286,276 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 66 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.